ANDROSTENEDIONE

OTHER NAME(S):

4-Androstene 3, 17-dione, 4-androstene-3,17-dione, Andro, Androstene, Androst-4-ene-3,17-dione, Androstenediona, Androsténédione.<br/><br/>

Overview

Overview Information

Androstenedione is a steroid hormone. It is used to make medicine.

Androstenedione is used to increase the production of the hormone testosterone to enhance athletic performance, build muscle, reduce body fat, increase energy, keep red blood cells healthy, and increase sexual desire and performance.

Androstenedione gained popularity as the supplement used by the baseball homerun hitter Mark McGwire and other professional sports players. In January 2005 legislation went into effect in the United States called the Anabolic Steroid Control Act of 2004. This reclassified androstenedione from a dietary supplement to an anabolic steroid, which is a schedule III controlled substance.

Androstenedione is considered a banned substance by the National Collegiate Athletic Association (NCAA).

How does it work?

Androstenedione is a steroid hormone used by the body to make testosterone and estrogen.

Uses

Uses & Effectiveness?

Likely InEffective for

  • Enhancing athletic performance. Taking androstenedione by mouth in doses of 100-300 mg per day does not significantly increase muscle strength, muscle size, or lean body mass when used for 2-3 months in connection with weight training.

Insufficient Evidence for

  • Increasing energy.
  • Red blood cell health.
  • Increasing sexual desire and function.
  • Other conditions.
More evidence is needed to rate the effectiveness of androstenedione for these uses.

Side Effects

Side Effects & Safety

Androstenedione is POSSIBLY UNSAFE for most people when taken by mouth. Some side effects experienced by men include reduced sperm production, shrunken testicles, painful or prolonged erections, breast development, behavioral changes, heart disease, and others. Women might develop masculine traits including deepening of the voice, facial hair, acne, male-pattern baldness, and coarsening of the skin. Women may also experience abnormal menstrual periods and depression. Androstenedione can increase the chances of getting cancers of the breast, prostate, or pancreas; and it is poisonous to the liver.

There is some concern that the strength and purity of androstenedione products may not match the product labeling.

Special Precautions & Warnings:

Pregnancy and breast-feeding: Androstenedione is LIKELY UNSAFE to use during pregnancy. It might bring on labor and cause a miscarriage.

Not enough is known about the safety of using androstenedione during breast-feeding. Stay on the safe side and avoid use.

Children: In children, androstenedione is LIKELY UNSAFE as it might stop bone growth and lead to shorter adult height. It might also cause early onset of puberty.

Depression: There is concern that androstenedione supplements might make depression worse in women. This is because some women with severe major depression have naturally high levels of androstenedione, so some people think there may be a connection. However, it is not known if taking androstenedione supplements causes depression.

Hormone-sensitive cancers and conditions: Androstenedione is the steroid hormone used by the body to make testosterone and estrogen. Taking androstenedione seems to increase estrogen levels. Men and women with hormone sensitive conditions should avoid androstenedione. Some of these conditions include breast, uterine, ovarian, and prostate cancer; endometriosis; and uterine fibroids.

Liver disease: There is some concern that androstenedione might harm the liver. So far, no such cases have been reported, but steroids similar to androstenedione have been connected to liver problems. Don't take androstenedione if you have any type of liver disease. Even if you don't have liver disease, it's best to get liver function tests if you take androstenedione.

Polycystic ovary syndrome (PCOS): There is concern that androstenedione supplements might worsen symptoms of PCOS. This is because women with PCOS have naturally high levels of androstenedione. But it is not known if taking androstenedione supplements actually worsens symptoms of PCOS.

Prostate cancer: There is some concern that androstenedione might increase the chances of developing prostate cancer. Developing research suggests that androstenedione can encourage prostate tumor cell growth. Don't use androstenedione if you have prostate cancer.

Interactions

Interactions?

Moderate Interaction

Be cautious with this combination

!
  • Estrogens interacts with ANDROSTENEDIONE

    Androstenedione seems to increase estrogen levels in the body. Taking androstenedione along with estrogen pills might cause too much estrogen in the body.<br /> Some estrogen pills include conjugated equine estrogens (Premarin), ethinyl estradiol, estradiol, and others.

Dosing

Dosing

The appropriate dose of androstenedione depends on several factors such as the user's age, health, and several other conditions. At this time there is not enough scientific information to determine an appropriate range of doses for androstenedione. Keep in mind that natural products are not always necessarily safe and dosages can be important. Be sure to follow relevant directions on product labels and consult your pharmacist or physician or other healthcare professional before using.

View References

REFERENCES:

  • Qunibi, W., Moustafa, M., Muenz, L. R., He, D. Y., Kessler, P. D., Diaz-Buxo, J. A., and Budoff, M. A 1-year randomized trial of calcium acetate versus sevelamer on progression of coronary artery calcification in hemodialysis patients with comparable lipid control: the Calcium Acetate Renagel Evaluation-2 (CARE-2) study. Am J Kidney Dis. 2008;51(6):952-965. View abstract.
  • Orwoll, E. S., Oviatt, S. K., McClung, M. R., Deftos, L. J., and Sexton, G. The rate of bone mineral loss in normal men and the effects of calcium and cholecalciferol supplementation. Ann.Intern.Med. 1-1-1990;112(1):29-34. View abstract.
  • Ott, S. M. and Chesnut, C. H., III. Calcitriol treatment is not effective in postmenopausal osteoporosis. Ann.Intern.Med. 2-15-1989;110(4):267-274. View abstract.
  • Overgaard, K. Effect of intranasal salmon calcitonin therapy on bone mass and bone turnover in early postmenopausal women: a dose-response study. Calcif Tissue Int 1994;55(2):82-86. View abstract.
  • Overgaard, K., Hansen, M. A., Jensen, S. B., and Christiansen, C. Effect of salcatonin given intranasally on bone mass and fracture rates in established osteoporosis: a dose-response study. BMJ 9-5-1992;305(6853):556-561. View abstract.
  • Overgaard, K., Riis, B. J., Christiansen, C., and Hansen, M. A. Effect of salcatonin given intranasally on early postmenopausal bone loss. BMJ 8-19-1989;299(6697):477-479. View abstract.
  • Overgaard, K., Riis, B. J., Christiansen, C., Podenphant, J., and Johansen, J. S. Nasal calcitonin for treatment of established osteoporosis. Clin Endocrinol (Oxf) 1989;30(4):435-442. View abstract.
  • Paccou, J., Viget, N., Legrout-Gerot, I., Yazdanpanah, Y., and Cortet, B. Bone loss in patients with HIV infection. Joint Bone Spine 2009;76(6):637-641. View abstract.
  • Paganini-Hill, A., Chao, A., Ross, R. K., and Henderson, B. E. Exercise and other factors in the prevention of hip fracture: the Leisure World study. Epidemiology 1991;2(1):16-25. View abstract.
  • Palacios, S., Castelo-Branco, C., Cifuentes, I., von, Helde S., Baro, L., Tapia-Ruano, C., Menendez, C., and Rueda, C. Changes in bone turnover markers after calcium-enriched milk supplementation in healthy postmenopausal women: a randomized, double-blind, prospective clinical trial. Menopause. 2005;12(1):63-68. View abstract.
  • Palmer, S. C., McGregor, D. O., and Strippoli, G. F. Interventions for preventing bone disease in kidney transplant recipients. Cochrane.Database.Syst.Rev. 2007;(3):CD005015. View abstract.
  • Palmer, S. C., Strippoli, G. F., and McGregor, D. O. Interventions for preventing bone disease in kidney transplant recipients: a systematic review of randomized controlled trials. Am J Kidney Dis. 2005;45(4):638-649. View abstract.
  • Palmer, S., McGregor, D. O., and Strippoli, G. F. Interventions for preventing bone disease in kidney transplant recipients. Cochrane.Database.Syst.Rev. 2005;(2):CD005015. View abstract.
  • Pan, W. H., Wang, C. Y., Li, L. A., Kao, L. S., and Yeh, S. H. No significant effect of calcium and vitamin D supplementation on blood pressure and calcium metabolism in elderly Chinese. Chin J Physiol 1993;36(2):85-94. View abstract.
  • Pannemans, D. L., Schaafsma, G., and Westerterp, K. R. Calcium excretion, apparent calcium absorption and calcium balance in young and elderly subjects: influence of protein intake. Br.J Nutr 1997;77(5):721-729. View abstract.
  • Papas, A. S., Clark, R. E., Martuscelli, G., O'Loughlin, K. T., Johansen, E., and Miller, K. B. A prospective, randomized trial for the prevention of mucositis in patients undergoing hematopoietic stem cell transplantation. Bone Marrow.Transplant. 2003;31(8):705-712. View abstract.
  • Park, Y., Leitzmann, M. F., Subar, A. F., Hollenbeck, A., and Schatzkin, A. Dairy food, calcium, and risk of cancer in the NIH-AARP Diet and Health Study. Arch Intern.Med. 2-23-2009;169(4):391-401. View abstract.
  • Patient level pooled analysis of 68 500 patients from seven major vitamin D fracture trials in US and Europe. BMJ 2010;340:b5463. View abstract.
  • Peacock, M., Liu, G., Carey, M., McClintock, R., Ambrosius, W., Hui, S., and Johnston, C. C. Effect of calcium or 25OH vitamin D3 dietary supplementation on bone loss at the hip in men and women over the age of 60. J Clin Endocrinol Metab 2000;85(9):3011-3019. View abstract.
  • Pentti, K., Tuppurainen, M. T., Honkanen, R., Sandini, L., Kroger, H., Alhava, E., and Saarikoski, S. Use of calcium supplements and the risk of coronary heart disease in 52-62-year-old women: The Kuopio Osteoporosis Risk Factor and Prevention Study. Maturitas 5-20-2009;63(1):73-78. View abstract.
  • Pereira, M. A., Jacobs, D. R., Jr., Van, Horn L., Slattery, M. L., Kartashov, A. I., and Ludwig, D. S. Dairy consumption, obesity, and the insulin resistance syndrome in young adults: the CARDIA Study. JAMA 4-24-2002;287(16):2081-2089. View abstract.
  • Perez-Jaraiz, M. D., Revilla, M., Alvarez de los Heros JI, Villa, L. F., and Rico, H. Prophylaxis of osteoporosis with calcium, estrogens and/or eelcatonin: comparative longitudinal study of bone mass. Maturitas 1996;23(3):327-332. View abstract.
  • Perrone, G., Galoppi, P., Valente, M., Capri, O., D'Ubaldo, C., Anelli, G., and Zichella, L. Intranasal salmon calcitonin in postmenopausal osteoporosis: effect of different therapeutic regimens on vertebral and peripheral bone density. Gynecol Obstet Invest 1992;33(3):168-171. View abstract.
  • Peters, R. K., Pike, M. C., Garabrant, D., and Mack, T. M. Diet and colon cancer in Los Angeles County, California. Cancer Causes Control 1992;3(5):457-473. View abstract.
  • Pfeifer, M., Begerow, B., Minne, H. W., Nachtigall, D., and Hansen, C. Effects of a short-term vitamin D(3) and calcium supplementation on blood pressure and parathyroid hormone levels in elderly women. J Clin Endocrinol Metab 2001;86(4):1633-1637. View abstract.
  • Pfeifer, M., Begerow, B., Minne, H. W., Suppan, K., Fahrleitner-Pammer, A., and Dobnig, H. Effects of a long-term vitamin D and calcium supplementation on falls and parameters of muscle function in community-dwelling older individuals. Osteoporos.Int 2009;20(2):315-322. View abstract.
  • Pflanz, S., Henderson, I. S., McElduff, N., and Jones, M. C. Calcium acetate versus calcium carbonate as phosphate-binding agents in chronic haemodialysis. Nephrol Dial.Transplant. 1994;9(8):1121-1124. View abstract.
  • Phelps, K. R., Stern, M., Slingerland, A., Heravi, M., Strogatz, D. S., and Haqqie, S. S. Metabolic and skeletal effects of low and high doses of calcium acetate in patients with preterminal chronic renal failure. Am J Nephrol 2002;22(5-6):445-454. View abstract.
  • Phillips, R. L. and Snowdon, D. A. Dietary relationships with fatal colorectal cancer among Seventh-Day Adventists. J Natl.Cancer Inst. 1985;74(2):307-317. View abstract.
  • Picard, D., Ste-Marie, L. G., Coutu, D., Carrier, L., Chartrand, R., Lepage, R., Fugere, P., and D'Amour, P. Premenopausal bone mineral content relates to height, weight and calcium intake during early adulthood. Bone Miner 1988;4(3):299-309. View abstract.
  • Pieper, A. K., Haffner, D., Hoppe, B., Dittrich, K., Offner, G., Bonzel, K. E., John, U., Frund, S., Klaus, G., Stubinger, A., Duker, G., and Querfeld, U. A randomized crossover trial comparing sevelamer with calcium acetate in children with CKD. Am J Kidney Dis. 2006;47(4):625-635. View abstract.
  • Pietinen, P., Malila, N., Virtanen, M., Hartman, T. J., Tangrea, J. A., Albanes, D., and Virtamo, J. Diet and risk of colorectal cancer in a cohort of Finnish men. Cancer Causes Control 1999;10(5):387-396. View abstract.
  • Pilz, S., Marz, W., Wellnitz, B., Seelhorst, U., Fahrleitner-Pammer, A., Dimai, H. P., Boehm, B. O., and Dobnig, H. Association of vitamin D deficiency with heart failure and sudden cardiac death in a large cross-sectional study of patients referred for coronary angiography. J Clin Endocrinol Metab 2008;93(10):3927-3935. View abstract.
  • Pitt, P., Li, F., Todd, P., Webber, D., Pack, S., and Moniz, C. A double blind placebo controlled study to determine the effects of intermittent cyclical etidronate on bone mineral density in patients on long-term oral corticosteroid treatment. Thorax 1998;53(5):351-356. View abstract.
  • Pittas, A. G., Dawson-Hughes, B., Li, T., Van Dam, R. M., Willett, W. C., Manson, J. E., and Hu, F. B. Vitamin D and calcium intake in relation to type 2 diabetes in women. Diabetes Care 2006;29(3):650-656. View abstract.
  • Polley, K. J., Nordin, B. E., Baghurst, P. A., Walker, C. J., and Chatterton, B. E. Effect of calcium supplementation on forearm bone mineral content in postmenopausal women: a prospective, sequential controlled trial. J Nutr 1987;117(11):1929-1935. View abstract.
  • Popescu M, Morris J, and Hillman L. Calcium and vitamin D supplementation in CF children [abstract]. Pediatric Pulmonology 1998;26(17):359.
  • Prentice, A., Ginty, F., Stear, S. J., Jones, S. C., Laskey, M. A., and Cole, T. J. Calcium supplementation increases stature and bone mineral mass of 16- to 18-year-old boys. J Clin Endocrinol Metab 2005;90(6):3153-3161. View abstract.
  • Prince, R. L., Devine, A., Dhaliwal, S. S., and Dick, I. M. Effects of calcium supplementation on clinical fracture and bone structure: results of a 5-year, double-blind, placebo-controlled trial in elderly women. Arch Intern.Med. 4-24-2006;166(8):869-875. View abstract.
  • Prince, R. L., Smith, M., Dick, I. M., Price, R. I., Webb, P. G., Henderson, N. K., and Harris, M. M. Prevention of postmenopausal osteoporosis. A comparative study of exercise, calcium supplementation, and hormone-replacement therapy. N.Engl.J Med. 10-24-1991;325(17):1189-1195. View abstract.
  • Prince, R., Devine, A., Dick, I., Criddle, A., Kerr, D., Kent, N., Price, R., and Randell, A. The effects of calcium supplementation (milk powder or tablets) and exercise on bone density in postmenopausal women. J Bone Miner Res 1995;10(7):1068-1075. View abstract.
  • Pritchard, R. S., Baron, J. A., and Gerhardsson, de, V. Dietary calcium, vitamin D, and the risk of colorectal cancer in Stockholm, Sweden. Cancer Epidemiol.Biomarkers Prev. 1996;5(11):897-900. View abstract.
  • Przybelski, R. J. and Binkley, N. C. Is vitamin D important for preserving cognition? A positive correlation of serum 25-hydroxyvitamin D concentration with cognitive function. Arch Biochem.Biophys. 4-15-2007;460(2):202-205. View abstract.
  • Psimenou E, Konstantinidou E, Giapraka N, and et al. Randomized controlled study of calcitonin and etidronate in the treatment of osteoporosis in renal transplant patients [abstract]. XIXth International Congress of the Transplantation Society 2002;
  • Barrett-Connor, E., Garland, C., McPhillips, J. B., Khaw, K. T., and Wingard, D. L. A prospective, population-based study of androstenedione, estrogens, and prostatic cancer. Cancer Res 1-1-1990;50(1):169-173. View abstract.
  • Broeder, C. E. Oral andro-related prohormone supplementation: do the potential risks outweigh the benefits? Can J Appl Physiol 2003;28(1):102-116. View abstract.
  • Brown, G. A., Vukovich, M., and King, D. S. Testosterone prohormone supplements. Med Sci Sports Exerc 2006;38(8):1451-1461. View abstract.
  • Catlin, D. H., Leder, B. Z., Ahrens, B. D., Hatton, C. K., and Finkelstein, J. S. Effects of androstenedione administration on epitestosterone metabolism in men. Steroids 2002;67(7):559-564. View abstract.
  • Cauley, J. A., Lucas, F. L., Kuller, L. H., Stone, K., Browner, W., and Cummings, S. R. Elevated serum estradiol and testosterone concentrations are associated with a high risk for breast cancer. Study of Osteoporotic Fractures Research Group. Ann Intern Med 2-16-1999;130(4 Pt 1):270-277. View abstract.
  • Fyssas, I., Syrigos, K. N., Konstandoulakis, M. M., Papadopoulos, S., Milingos, N., Anapliotou, M., Waxman, J., and Golematis, B. C. Sex hormone levels in the serum of patients with pancreatic adenocarcinoma. Horm Metab Res 1997;29(3):115-118. View abstract.
  • Horton, R. and Tait, J. F. Androstenedione production and interconversion rates measured in peripheral blood and studies on the possible site of its conversion to testosterone. J Clin Invest 1966;45(3):301-313. View abstract.
  • Kohut, M. L., Thompson, J. R., Campbell, J., Brown, G. A., Vukovich, M. D., Jackson, D. A., and King, D. S. Ingestion of a dietary supplement containing dehydroepiandrosterone (DHEA) and androstenedione has minimal effect on immune function in middle-aged men. J Am Coll Nutr 2003;22(5):363-371. View abstract.
  • Leder, B. Z., Catlin, D. H., Longcope, C., Ahrens, B., Schoenfeld, D. A., and Finkelstein, J. S. Metabolism of orally administered androstenedione in young men. J Clin Endocrinol Metab 2001;86(8):3654-3658. View abstract.
  • Uralets, V. P. and Gillette, P. A. Over-the-counter anabolic steroids 4-androsten-3,17-dione; 4-androsten-3beta,17beta-diol; and 19-nor-4-androsten-3,17-dione: excretion studies in men. J Anal Toxicol 1999;23(5):357-366. View abstract.
  • van, Gammeren D., Falk, D., and Antonio, J. Effects of norandrostenedione and norandrostenediol in resistance-trained men. Nutrition 2002;18(9):734-737. View abstract.
  • van, Gammeren D., Falk, D., and Antonio, J. The effects of supplementation with 19-nor-4-androstene-3,17-dione and 19-nor-4-androstene-3,17-diol on body composition and athletic performance in previously weight-trained male athletes. Eur J Appl Physiol 2001;84(5):426-431. View abstract.
  • Anabolic Steroid Act, Public Law No. 108-358, 2004.
  • Anon. Creatine and androstenedione, two dietary supplements. Med Lett Drugs Ther 1998;40:105-6.
  • Beckham SG, Earnest CP. Four weeks of androstenedione supplementation diminishes the treatment response in middle aged men. Br J Sports Med 2003;37:212-8.. View abstract.
  • Broeder CE, Quindry J, Brittingham K, et al. The Andro Project: physiological and hormonal influences of androstenedione supplementation in men 35 to 65 years old participating in a high-intensity resistance training program. Arch Intern Med 2000;160:3093-104. View abstract.
  • Brown GA, Vukovich MD, Martini ER, et al. Endocrine responses to chronic androstenedione intake in 30- to 56-year-old men. J Clin Endocrinol Metab 2000;85:4074-80. View abstract.
  • Brown GA, Vukovich MD, Martini ER, et al. Effects of androstenedione-herbal supplementation on serum sex hormone concentrations in 30- to 59-year-old men. Int J Vitam Nutr Res 2001;71:293-301. View abstract.
  • Brown GA, Vukovich MD, Reifenrath TA, et al. Effects of anabolic precursors on serum testosterone concentrations and adaptations to resistance training in young men. Int J Sport Nutr Exerc Metab 2000;10:340-59. View abstract.
  • Catlin DH, Leder BZ, Ahrens B, et al. Trace contamination of over-the-counter androstenedione and positive urine test results for a nandrolone metabolite. JAMA 2000;284:2618-21. View abstract.
  • Green GA, Catlin DH, Starcevic B. Analysis of over-the-counter dietary supplements. Clin J Sport Med 2001;11:254-9.. View abstract.
  • Health and Human Services. HHS launches crackdown on products containing Andro. March, 2004.
  • Hoque A, Yao S, Till C, et al. Effect of finasteride on serum androstenedione and risk of prostate cancer within the prostate cancer prevention trial: differential effect on high- and low-grade disease. Urology. 2015;85(3):616-20. View abstract.
  • Judge LW, Bellar DM, Hoover DL, Biggs D, Leitzelar BN, Craig BW. Effects of acute androstenedione supplementation on testosterone levels in older men. Aging Male. 2016;19(3):161-167. View abstract.
  • Kachhi PN, Henderson SO. Priapism after androstenedione intake for athletic performance enhancement. Ann Emerg Med 2000;35:391-3. View abstract.
  • Kicman, A. T., Bassindale, T., Cowan, D. A., Dale, S., Hutt, A. J., and Leeds, A. R. Effect of androstenedione ingestion on plasma testosterone in young women; a dietary supplement with potential health risks. Clin Chem 2003;49(1):167-169. View abstract.
  • King DS, Sharp RL, Vukovich MD, et al. Effect of oral androstenedione on serum testosterone and adaptations to resistance training in young men. A randomized controlled trial. JAMA 1999;281:2020-8. View abstract.
  • Leder BZ, Longcope C, Catlin DH, et al. Oral androstenedione administration and serum testosterone concentrations in young men. JAMA 2000;283:779-82. View abstract.
  • Leder, B. Z., Leblanc, K. M., Longcope, C., Lee, H., Catlin, D. H., and Finkelstein, J. S. Effects of oral androstenedione administration on serum testosterone and estradiol levels in postmenopausal women. J Clin Endocrinol Metab 2002;87(12):5449-5454. View abstract.
  • Mecenas CA, Giussani DA, Owiny JR, et al. Production of premature delivery in pregnant rhesus monkeys by androstenedione infusion. Nat Med 1996;2:443-8. View abstract.
  • National Collegiate Athletic Association. NCAA Banned-Drug Classes 2005-2006. Available at: http://www1.ncaa.org/membership/ed_outreach/health-safety/drug_testing/banned_drug_classes.pdf.
  • Rasmussen BB, Volpi E, Gore DC, Wolfe RR. Androstenedione does not stimulate muscle anabolism in young healthy men. J Clin Endocrinol Metab 2000;85:55-9. View abstract.
  • Ritter RH, Cryar AK, Hermans MR. Oral androstenedione-induced impotence and severe oligospermia. Fertil Steril. 2005;84(1):217. View abstract.
  • Roth MY, Page ST, Lin K, et al. The effect of gonadotropin withdrawal and stimulation with human chorionic gonadotropin on intratesticular androstenedione and DHEA in normal men. J Clin Endocrinol Metab. 2011;96(4):1175-81. View abstract.
  • Sathyapalan T, Smith KA, Coady AM, Kilpatrick ES, Atkin SL. Atorvastatin therapy decreases androstenedione and dehydroepiandrosterone sulphate concentrations in patients with polycystic ovary syndrome: randomized controlled study. Ann Clin Biochem. 2012;49(Pt 1):80-5. View abstract.
  • van Weerden WM, van Kreuningen A, Elissen NM, et al. Effects of adrenal androgens on the transplantable human prostate tumor PC-82. Endocrinol 1992;131:2909-13. View abstract.
  • Vierck JL, Icenoggle DL, Bucci L, Dodson MV. The effects of ergogenic compounds on myogenic satellite cells. Med Sci Sports Exerc 2003;35:769-76. View abstract.
  • Wallace MB, Lim J, Cutler A, Bucci L. Effects of dehydroepiandrosterone vs androstenedione supplementation in men. Med Sci Sports Exerc 1999;31:1788-92. View abstract.
  • Weber B, Lewicka S, Deuschle M, et al. Testosterone, androstenedione and dihydrotestosterone concentrations are elevated in female patients with major depression. Psychoneuroendocrinology 2000;25:765-71. View abstract.

Vitamins Survey

Have you ever purchased ANDROSTENEDIONE?

Did you or will you purchase this product in-store or online?

Where did you or where do you plan to purchase this product?

Where did you or where do you plan to purchase this product?

What factors influenced or will influence your purchase? (check all that apply)

Vitamins Survey

Where did you or where do you plan to purchase this product?

Do you buy vitamins online or instore?

What factors are most important to you? (check all that apply)

More Resources for ANDROSTENEDIONE

CONDITIONS OF USE AND IMPORTANT INFORMATION: This information is meant to supplement, not replace advice from your doctor or healthcare provider and is not meant to cover all possible uses, precautions, interactions or adverse effects. This information may not fit your specific health circumstances. Never delay or disregard seeking professional medical advice from your doctor or other qualified health care provider because of something you have read on WebMD. You should always speak with your doctor or health care professional before you start, stop, or change any prescribed part of your health care plan or treatment and to determine what course of therapy is right for you.

This copyrighted material is provided by Natural Medicines Comprehensive Database Consumer Version. Information from this source is evidence-based and objective, and without commercial influence. For professional medical information on natural medicines, see Natural Medicines Comprehensive Database Professional Version.
© Therapeutic Research Faculty 2018.